retatrutide phase 2 Great news again!!! A trial of (Triple–Hormone-Receptor Agonist) for obesity. At 48 wks the median body weight loss was 24.2% and >5%, >10% and >15% had occurred in 100% The loudest people online are

I wonder if will work so we will see in next few weeks

Safety check A licensed clinician still needs to review health history, contraindications, current medications, side effects, and dose escalation

According to Mercks financial report, Keytrudas Q1 2025 sales reached $7.21 billion, up 4% year-over-year, but with a quarter-over-quarter decline for the first time

Clinicians are faced with untangling many differences in trial design and patient characteristics, and an absence of any direct head-to-head insights

Cardiovascular benefits are particularly relevant for women over 40, who face increasing heart disease risk after menopause

Plans should also ensure Wegovy is added to a transition exclusion list to ensure only Part D eligible medically accepted indications are afforded a transition fill